

MINUTES

Aroostook County Opioid Task Force Review Committee
Thursday, January 30, 2025 12:00 PM
Administrative Hearing Room – Caribou Courthouse

Present:

Ryan D. Pelletier - County Administrator
Michael Greenlaw - Review Committee Member
Freeman Corey, Review Committee Member
Brooke Nadeau – Review Committee Member
Dr. Samuela Manages- Review Committee Member - Zoom
Amy Ward – Review Committee Member
Steve Pelletier, ARPA Administrator
Tammy Pelletier, Operations Assistant

1. Mr. Ryan Pelletier called the meeting to order at 12:00 PM.
2. Mr. Ryan Pelletier opened the floor to the review and scoring of the applications that were received. Mr. Steve Pelletier went through each application and scoring individually. The following were the scores as agreed upon by the review committee:

Applicant	Pillar	Score
ACAP	Recovery	98
AMHC	Treatment	91
Michael's Active Recovery	Recovery	102
Mi'kmaq Nation	Harm Reduction	94
Northern Maine Wellness Clinic	Treatment	98

3. Mr. Ryan Pelletier began the discussion on what the recommendation should be to the Commissioners for funding disbursement. Funding requested was \$350,000 and the allocated amount available is \$300,000. Funding was not equally distributed across the 4 pillars as intended at \$75,000 available for each category. The committee voted on each application to determine funding recommendation amounts as outlined for a total funding amount of \$300,000:

Applicant	Pillar	Score	Request	Award	Vote
ACAP	Recovery	98	\$75,000	\$75,000	5 Yeas, 0 Nays
AMHC	Treatment	91	\$75,000	\$50,000	5 Yeas, 0 Nays
Michael's Active Recovery	Recovery	102	\$75,000	\$75,000	5 Yeas, 0 Nays
Mi'kmaq Nation	Harm Reduction	94	\$50,000	\$50,000	5 Yeas, 0 Nays
Northern Maine Wellness Clinic	Treatment	98	\$75,000	\$50,000	5 Yeas, 0 Nays

4. Mr. Ryan Pelletier advised that the recommendation would be put forth to the Commissioners on February 19th for approval. If approved, applicants would be notified within 1 week and the County would begin the contract agreement process with each recipient.
5. Mr. Ryan Pelletier adjourned the meeting at 1:30 PM.



WELCOME!

Agenda

- Introduction
- Grantee Updates
- Update on Aroostook Drug Treatment Court
- 2026 Changes
- Next Round – Timeline Review
- Final Tips & Takeaways



OPIOID SETTLEMENT FUNDS



Awardees	Total Awarded	Money Spent	Difference	% of award left	Summary	
AMHC	\$50,000.00	\$19,400.47	-\$30,599.53	-61.20%	Total Money Disbursed	\$83,584.30
Michael's Active Recovery	\$75,000.00	\$11,716.37	-\$63,283.63	-84.38%		
Mi'kmaq	\$50,000.00	\$4,979.46	-\$45,020.54	-90.04%		✘
ACAP	\$75,000.00	\$0.00	-\$75,000.00	-100.00%		
Northern Maine Wellness	\$50,000.00	\$47,488.00	-\$2,512.00	-5.02%		
Total	\$300,000.00	\$83,584.30	-\$216,415.70	-72.14%		

Northern Maine Wellness





6 months of progress





Power of Engagement



Mi'kmaq Nation Community Outreach

22 individuals were given access to harm reduction supplies such as Naloxone, testing strips, and sharp containers.



AMHC

Aroostook Mental Health Center

March – 2,681 calls managed

April – 2,302 calls managed

May – 2,408 calls managed

Despite temporary staffing shortages, AMHC's Call Center maintained high service capacity, with over 7,300 calls managed in three months and 100+ individuals connected to SUD treatment with same-day or same-week access. Opiate Settlement funds are directly supporting workforce stability and the integration of peer-informed recovery support services. These efforts are critical in meeting the urgent behavioral health needs of individuals in Aroostook County and surrounding regions.



Michael's Active Recovery

Continuing their community events and outreach, along with recovery coaching, and weekly peer-led support meetings.

Attending the 7th Annual Opioid Response Summit.

Naloxone trainings and distribution.



CHANGES?

WHAT WORKED?

WHAT DID NOT?

Letter of Intent

Application

Scoring

Advertising

Requirements for submission*



ROUND II TIMELINE

Press Release – September

Letter of Intent – Due?

Application Deadline - ?

Recommendation to Commissioners – Month?

Award Letters & Contracts to follow immediately

Thank you

April Duffy

207-493-0461

april@aroostook.me.us





Aroostook County is finally getting a drug treatment court

by [Kathleen Phalen Tomaselli](#)

July 29, 2025

A new Maine law paves the way for a drug treatment court to open in Aroostook County, with \$740,783 provided for staff and services.

Last week, Gov. Janet Mills signed into law [LD 779](#), An Act to Fund the Aroostook County Drug Treatment Court. The bill, sponsored by Sen. Anne Carney, D-Cape Elizabeth, ensures that The County's drug court will finally become operational.

"All Mainers, no matter where they live, deserve access to justice and recovery," Carney said in a statement. "It's an issue personally close to my heart, as services like this could have helped save my brother's life before he lost his battle against substance use disorder. This is a critical investment that will help protect lives in a region of our state where it is needed most."

There is a history of efforts to create a treatment court in Aroostook County that began with a 2023 bill, [LD 1596](#), sponsored by former Senate President Troy Jackson, D-Allagash. Until now, there was no comparable service for people living in Maine's northern region, leaving recovery behind bars as the only option.

Treatment and recovery courts, known in Maine as [specialty dockets](#), offer an alternative to jail for people with substance use disorder. Applicants must go through a screening process and plead guilty to their alleged crimes. The program includes intensive treatment for substance use and other issues, as well as regular supervision.

According to research, drug treatment courts reduce criminal recidivism, improve quality of life and enhance public safety, Elizabeth Simoni, executive director of Maine Pretrial Services, said in support of the bill.

"Our tools in responding to the drug problem are rough — jail and the threat of jail," Aroostook County District Attorney Todd Collins said in his testimony in support of the

bill. “I do not see how we can, in good conscience, wait for someone to kill, injure, maim, burglarize, rob, or steal before we step in and demand a ‘serious’ response to a serious problem.”

Still, in 2023, a legislative committee decided The County’s drug treatment court needed a more comprehensive plan prior to approval. A stakeholders working committee led by Collins was established.

There are now six state [adult treatment drug courts](#) located in Androscoggin, Cumberland, Oxford, Penobscot, Washington and York counties.

For people in Aroostook, the closest similar option has been in Calais, more than 130 miles away from The County’s population center.

In 2024, the Legislature approved The County’s treatment court and the \$740,000 in funding, but it remained out of reach after the funding [failed to materialize](#) when the House of Representatives did not consider the measure.

“To come this close to establishing and funding a drug court in Aroostook County only for politics to get in the way is heartbreaking,” Jackson said at the time.

LD 779 allocates funds to the behavioral health office in the Maine Department of Health and Human Services to allow it to contract with an organization to provide pre-trial services at the Aroostook County Drug Treatment Court. It also funds a new assistant district attorney position and the provision of public defense services at the court.

The funding in this bill is scheduled to become available after July 1, 2026.

From: Shayna E. Sacks <SSacks@NapoliLaw.com>

Sent: Tuesday, July 15, 2025 2:12 PM

To: Ryan D. Pelletier <ryan@aroostook.me.us>

Cc: jbelleau@tmbf-law.com; ALee@tmbf-law.com

Subject: Opioids: Additional Manufacturer Settlements (attorney client settlement communication)

We are happy to notify you of a new opioid settlement opportunity that will resolve all of your claims against each of the below small manufacturer companies in one participation agreement. These settlements will collectively add an additional \$1.1 billion in cash and pharmaceutical product to be distributed among state and local governments across the country.

1. Alvogen, Inc.;
2. Amneal Pharmaceuticals, Inc.;
3. Apotex Inc.;
4. Hikma Pharmaceuticals USA Inc.;
5. Indivior Inc.;
6. Mylan Pharmaceuticals Inc.;
7. Sun Pharmaceutical Industries, Inc.; and
8. Zydus Pharmaceuticals (USA), Inc.

We recommend that you join this settlement group by signing and returning the Participation Agreement via DocuSign.

Six of the nine settlements will be paid out in the first year, with the remaining three (Amneal, Indivior and Mylan) paid over a period of between two and ten years. Three of the settlements include opioids overdose product such as Naloxone. Eight of the settlement also contain injunctive relief concerning their opioid marketing and suspicious monitoring programs that will be overseen by the States.

You do not need to have sued these companies in order to participate in these settlements. This settlement group will utilize the same allocation formula as the prior national agreements. This means that your state will receive the same share of the settlements that they have in the past pursuant to the state agreement, and the local governments will receive funding under the same process as in previous national settlements. As in past deals, attorney fees and costs will be paid out of a separate fund.

This notice is different than the notice you recently received from Rubris concerning a settlement with Purdue Pharma, L.P., and the Sackler Family. You may participate in the settlements discussed in this notice regardless of whether you join the Purdue and Sackler settlement.

You will receive a *Notice* this week, and a *Participation Agreement* with other documents to consider, directly from Rubris in July/August 2025. There will be one *Participation Agreement* for the entire settlement group. **You will need to obtain the necessary authorization and submit the *Settlement Participation Agreement* for this settlement group on or before September 30, 2025.**

I am available as always to discuss. Hope you are well.

Shayna E. Sacks

Partner

Shayna E. Sacks

Partner

Admitted in: NY, NJ, CT

To: Aroostook County, ME

Rubris Reference Number: CL-1770686

**NOTICE OF NEW NATIONAL OPIOID SETTLEMENTS
AND UPCOMING ACTION NEEDED TO PARTICIPATE**

New national opioid settlements have been reached with Alvogen, Amneal, Apotex, Hikma, Indivior, Mylan, Sun, and Zydus. This is the formal notice required by the settlements and authorized by the parties.

Please read this email and the attached document carefully.

You are receiving this notice because your State has elected to participate in one or more of the eight national opioid settlements with Alvogen, Amneal, Apotex, Hikma, Indivior, Mylan, Sun, and Zydus. The list of participating states for each settlement can be found at <https://nationalopioidsettlement.com>. Your subdivision or special district may participate in each settlement for which your State has elected to participate.

Your subdivision or special district might have participated in prior national opioid settlements, including those with Johnson & Johnson/Janssen, Cardinal, AmerisourceBergen, McKesson, Teva, Allergan, CVS, Walgreens, Walmart, or Kroger. This notice concerns the opportunity to participate in one or more of the new settlements with eight new Settling Defendants (Alvogen, Amneal, Apotex, Hikma, Indivior, Mylan, Sun, and Zydus). Your subdivision or special district may participate in a new settlement even if it did not participate in a prior national settlement.

In the next few weeks, you will receive additional information and documentation to sign and return if you wish to join the new settlements. Please review the list of individuals on this email and contact the Opioids Implementation Administrator at opioidsparticipation@rubris.com if someone else at your subdivision or special district should receive communications about these settlements.

Your subdivision or special district must "opt in" to participate in the new settlements. To do so, you must sign and return the documentation that you will be receiving in the next few weeks.

This notice is different than the notice you recently received from Rubris concerning a settlement with Purdue Pharma, L.P, and the Sackler Family. The settlements discussed in this notice are different than the settlement with Purdue and the Sacklers, and you may participate in the settlements discussed in this notice regardless of whether you join the Purdue and Sackler settlement.

The deadline to return the required documentation is October 8, 2025. *Documentation submitted for prior national settlements is not applicable to the new settlements.*

The attached document provides additional information concerning the new national opioids settlements involving Alvogen, Amneal, Apotex, Hikma, Indivior, Mylan, Sun, and Zydus.

Questions about this notice or the process for receiving and submitting the required Settlement Participation Forms may be directed to your attorney, the Opioids Implementation Administrator at opioidsparticipation@rubris.com, or your Attorney General's Office.

If your subdivision or special district is represented by an attorney with respect to opioid claims and they are not copied on this message, please immediately contact them concerning this notice.

Thank you,

National Opioids Settlements Implementation Administrator
National Alvogen, Amneal, Apotex, Hikma, Indivior, Mylan, Sun, and Zydus Settlements

The Implementation Administrator is retained to provide the settlement notice required by the respective settlement agreements referenced above and to manage the collection of settlement participation forms for each settlement.

National Opioids Settlements: Alvogen, Amneal, Apotex, Hikma, Indivior, Mylan, Sun, Zydus
Opioids Implementation Administrator
opioidsparticipation@rubris.com

Aroostook County, ME
Rubris Reference Number: CL-1770686

**TO LOCAL POLITICAL SUBDIVISIONS AND SPECIAL DISTRICTS:
THIS NOTICE CONTAINS IMPORTANT INFORMATION ABOUT NATIONAL OPIOID
SETTLEMENTS.**

SETTLEMENT OVERVIEW

Proposed nationwide settlement agreements (“Settlements”) have been reached that would resolve opioid litigation brought by states, local political subdivisions, and special districts against eight opioids manufacturers, Alvogen, Amneal, Apotex, Hikma, Indivior, Mylan, Sun, and Zydus (the “Manufacturers”). Local political subdivisions and special districts are referred to as “subdivisions.”

The Settlements require the settling Manufacturers to pay hundreds of millions of dollars to abate the opioid epidemic. The Settlements will provide a maximum of approximately \$720 million in cash to participating states and subdivisions to remediate and abate the impacts of the opioid crisis. Depending on participation by states and subdivisions, the Settlements require:

- Alvogen to immediately pay up to approximately \$19 million;
- Amneal to pay up to approximately \$74 million over 10 years, and to provide either approximately \$177 million of its generic version of the drug Narcan or up to an additional approximately \$44 million in cash;
- Apotex to immediately pay up to approximately \$65 million;
- Hikma to immediately pay up to approximately \$98 million, and to provide either approximately \$35 million of its naloxone product or up to an additional approximately \$7 million in cash;
- Indivior to pay up to approximately \$75 million over five years, a portion of which, at the election of the state, could be paid in the form of Indivior’s branded buprenorphine and/or nalmefene products with a value of up to \$140 million.;
- Mylan to pay up to approximately \$290 million over nine years;
- Sun to immediately pay up to approximately \$32 million; and
- Zydus to immediately pay up to approximately \$15 million.

The Settlements also contain injunctive relief governing opioid marketing, sale, distribution, and/or distribution practices and require the Manufacturers to implement safeguards to prevent diversion of prescription opioids.

Each of the proposed settlements has two key participation steps.

First, each eligible state decides whether to participate in each Settlement. A list of participating states for each settlement can be found at <https://nationalopioidsettlement.com/>.

Second, eligible subdivisions within each participating state decide whether to participate in each Settlement. The more subdivisions that participate, the more funds flow to that state and its subdivisions. Any subdivision that does not participate cannot directly share in any of the settlement funds, even if the subdivision’s state is settling and other participating subdivisions are sharing in settlement funds. If the state does not participate in a particular Settlement, the subdivisions in that state are not eligible to participate in that Settlement.

WHO IS RUBRIS INC. AND WHAT IS THE IMPLEMENTATION ADMINISTRATOR?

The Settlements provide that an Implementation Administrator will provide notice and manage the collection of participation forms. Rubris Inc. is the Implementation Administrator for these new Settlements and was also retained for the prior national opioid settlements.

WHY IS YOUR SUBDIVISION RECEIVING THIS NOTICE?

Your state has elected to participate in one or more of the Settlements, and your subdivision may participate in those Settlements in which your state has elected to participate. This notice is also sent directly to counsel for such subdivisions if the Implementation Administrator has their information.

If you are represented by an attorney with respect to opioid claims, please contact them.

Subdivisions can participate in the Settlements whether or not they filed a lawsuit or are represented.

WHERE CAN YOU FIND MORE INFORMATION?

Detailed information about the Settlements, including each settlement agreement, may be found at: <https://nationalopioidsettlement.com>. This website also includes information about how the Settlements are being implemented in most states and how funds will be allocated within your state.

You are encouraged to review the settlement agreement terms and discuss the terms and benefits with your counsel, your Attorney General's Office, and other contacts within your state. Information and documents regarding the Settlements and your state allocation can be found on the settlement website at <https://nationalopioidsettlement.com/>.

Your subdivision will need to decide whether to participate in the proposed Settlements, and subdivisions are encouraged to work through this process before the ***October 8, 2025*** deadline.

HOW DO YOU PARTICIPATE IN THE SETTLEMENTS?

The Settlements require that you take affirmative steps to "opt in" to the Settlements.

In the next few weeks, you will receive documentation and instructions from the Implementation Administrator or, in some cases, your Attorney General's Office. In order to participate in a settlement, a subdivision must sign and return the required Participation Form for that settlement.

Please add the following email addresses to your "safe" list so emails do not go to spam / junk folders: dse_na3@docusign.net and opioidsparticipation@rubris.com. Please monitor your email for the Participation Forms and instructions.

All required documentation must be signed and returned on or before ***October 8, 2025***.

From: National Opioid Settlements Implementation Administrator

<opioidsparticipation@rubris.com>

Sent: Thursday, July 3, 2025 1:27 PM

To: Ryan D. Pelletier <ryan@aroostook.me.us>

Cc: Shayna Sacks <ssacks@napolilaw.com>; Dana Gendreau

<dana.gendreau@aroostook.me.us>

Subject: NEW NATIONAL OPIOID SETTLEMENT NOTICE - Purdue - RefNum CL-1748273

To: Aroostook County, ME

Rubris Reference Number: CL-1748273

**NOTICE OF NEW NATIONAL OPIOID SETTLEMENT
AND UPCOMING ACTION NEEDED TO PARTICIPATE**

This notice concerns the opportunity to participate in a proposed nationwide settlement agreement that has been reached with Purdue (and certain of its affiliates) and the Sackler family concerning alleged misconduct related to opioids.

Please read this email and the attached document carefully. The attached document provides additional information concerning the new proposed national opioid settlement involving Purdue and the Sacklers.

Your subdivision might have participated in the national opioid settlements with Johnson & Johnson/Janssen, the three Distributors (Cardinal, AmerisourceBergen (Cencora), and McKesson), Teva, Allergan, CVS, Walgreens, and Walmart, and/or Kroger Co. Your subdivision may participate in the settlement even if it did not participate in a prior national settlement. Additionally, your subdivision may participate in the settlement whether or not it sued Purdue or the Sacklers.

In the next few weeks, you will receive additional information and documentation to sign and return if you wish to join the new proposed national opioid settlement with Purdue and the Sacklers. Please review the list of individuals on this email and contact the Implementation Administrator at opioidsparticipation@rubris.com if someone else at your subdivision should receive communications about this settlement.

Questions about this notice or the process for receiving and submitting the required Settlement Participation Forms may be directed to your attorney, the Implementation Administrator at opioidsparticipation@rubris.com, or your Attorney General's Office.

If your subdivision is represented by an attorney with respect to opioid claims and they are not copied on this message, please immediately contact them concerning this notice.

Thank you,

Implementation Administrator for the Direct Settlement

The Implementation Administrator is retained to provide the settlement notice required by the respective settlement agreements referenced above and to manage the collection of settlement participation forms for each settlement.

National Opioid Settlement: Purdue Pharma L.P.
Rubris Reference Number: CL-1748273

***TO LOCAL POLITICAL SUBDIVISIONS:
THIS NOTICE CONTAINS IMPORTANT INFORMATION ABOUT A NEW
NATIONAL OPIOID SETTLEMENT.***

PURDUE PHARMA L.P. & SACKLER FAMILY SETTLEMENT OVERVIEW

A proposed nationwide settlement agreement has been reached with Purdue (and certain of its affiliates) and the Sackler family concerning alleged misconduct related to opioids.

The proposed settlement is being implemented in connection with Purdue's bankruptcy proceedings, and consists of, among other things, a settlement of Purdue's claims against the Sacklers and certain other parties (referred to as the "Estate Settlement"), and a settlement of direct claims against the Sacklers held by States, local governments and other creditors (the "Direct Settlement", and together with the Estate Settlement, the "Settlement"). The Settlement contemplates that the Sacklers will be paying an aggregate of \$6.5 billion in 16 payments over 15 years, including \$1.5 billion on the settlement's Effective Date (expected to be in 2026), though some amounts are subject to discounted prepayments. These amounts are in addition to amounts available from the Purdue estate including amounts available on the Effective Date (expected to be around \$900 million) and amounts that may be paid in the future.

The Settlement also contains injunctive relief governing opioid dispensing practices and requires the successor-in-interest of Purdue Pharma L.P. to implement safeguards to prevent diversion of prescription opioids, and also restrict certain Sacklers from directly or indirectly engaging in the manufacturing or sale of opioids, as detailed in the Settlement.

The proposed settlement has two key participation steps now that **all eligible states and territories elected to participate in the Direct Settlement.**

First, eligible subdivisions within each participating state decide whether to participate in the Direct Settlement. The Direct Settlement is documented in the Governmental Entity and Shareholder Direct Settlement Agreement, which is commonly referred to as the "GESA". The more subdivisions that participate, the more funds flow to that state and its subdivisions. Any subdivision that does not participate cannot directly share in any of the Direct Settlement funds, even if the subdivision's state is settling and other participating subdivisions are sharing in settlement funds.

YOU MUST PARTICIPATE IN THE DIRECT SETTLEMENT BY RETURNING YOUR PARTICIPATION FORM IN ORDER TO RECEIVE THE BENEFITS OF THE SETTLEMENT.

Second, concurrently with the solicitation of eligible subdivisions to participate in the Direct Settlement, votes will be solicited for approval of Purdue Pharma L.P.'s bankruptcy plan, which plan will provide distributions in respect of the Estate Settlement. **NOT ALL SUBDIVISIONS ELIGIBLE TO PARTICIPATE IN THE SETTLEMENT WILL RECEIVE PACKAGES TO VOTE ON THE PLAN.**

Please note that this is NOT a solicitation or a request for subdivisions to submit votes on the Purdue bankruptcy plan. This settlement package only pertains to a decision to participate in the Direct Settlement with the Sacklers.

If you receive a package to vote on the plan you should follow the applicable instructions for voting. PLEASE NOTE THAT VOTING ON THE PLAN IS SEPARATE FROM PARTICIPATION IN THE DIRECT SETTLEMENT. **IT IS NOT NECESSARY TO VOTE ON THE PLAN IN ORDER TO RECEIVE THE BENEFITS OF THE SETTLEMENT.**

WHO IS RUBRIS INC. AND WHAT IS THE IMPLEMENTATION ADMINISTRATOR?

The Direct Settlement provides that an Implementation Administrator will provide notice and manage the collection of participation forms. Rubris Inc. is the Implementation Administrator for the Direct Settlement and was also retained for the prior national opioid settlements.

WHY IS YOUR SUBDIVISION RECEIVING THIS NOTICE?

Your state has elected to participate in the Settlement, and therefore your subdivision may participate in the Direct Settlement. This notice is also being sent directly to counsel for such subdivisions if the Implementation Administrator has their information.

If you are represented by an attorney with respect to opioid claims, please contact them. **Subdivisions can participate in the Settlement whether or not they filed a lawsuit or are represented.**

WHERE CAN YOU FIND MORE INFORMATION?

Detailed information about the Settlement, including each settlement agreement, may be found at: <https://nationalopioidsettlement.com/purdue-sacklers-settlements/>. This website will be updated to include information about how the Settlement is being implemented in most states and how funds will be allocated within your state.

You are encouraged to review the terms of the settlement agreements and discuss the terms and benefits with your counsel, your Attorney General's Office, and other contacts within your state.

Your subdivision will need to decide whether to participate in the proposed Settlement, and subdivisions are encouraged to work through this process before the **September 30, 2025** deadline.

HOW DO YOU PARTICIPATE IN THE SETTLEMENT?

The Settlement requires that you take affirmative steps to "opt in" to the Settlement.

In the next few weeks, you will receive documentation and instructions from the Implementation Administrator. In order to participate in the settlement, a subdivision must sign and return the required documentation.

Please add the following email addresses to your "safe" list so emails do not go to spam / junk folders: dse_na3@docusign.net and opioidsparticipation@rubris.com. Please monitor your email for the Participation Form and instructions.

All required documentation must be signed and returned on or before **September 30, 2025**.

County of Aroostook

COMMISSIONERS' OFFICE

FINANCE DIRECTOR / DEPUTY TREASURER
Dana L. Gendreau



COUNTY COMMISSIONERS

PAUL J. UNDERWOOD
PRESQUE ISLE

NORMAN L. FOURNIER
WALLAGRASS

WILLIAM T. DOBBINS
HOULTON

August 8, 2025

Subject: Update on Opioid Settlement Funds

To date, the County has received \$877,879 of opioid settlement funds. Projected over the next 13 years, the County of Aroostook is estimated to receive an additional \$1.8 million of settlement funds which would bring the projected grand total settlement to \$2,732,268.

Payment Year	Amount Received	Amount <i>*Estimated</i> to Receive
2022	\$325,483	-
2023	\$65,897	-
2024	\$427,965	\$21,710
2024: McKinsey Subdivision Class Action	\$41,650	-
2025	\$16,884	\$139,843
2026-2038		\$1,692,836
TOTAL	\$877,879	\$1,854,389

**Estimated payments are subject to change. Last updated 7/1/25 by the Office of the Maine Attorney General.*

Financial Summary of Opioid Activity as of August 8, 2025

Revenue: \$877,879

County Jail Mat Program Expense Paid: (\$75,000)

Round 1 Grant Award Expenses Paid: (\$83,581)

Round 1 Grant Award Funds Restricted: (216,419)

Opioid Fund Balance: \$502,879

Regards,

Dana Gendreau
Finance Director/Deputy Treasurer



*Aroostook County Commissioners' Office
Aroostook County
144 Sweden Street, Suite 1
Caribou, Maine 04736*

AROOSTOOK COUNTY OPIOID SETTLEMENT FUND LETTER OF INTENT

**All Letters of Intent must be received by mail or electronically
by 4 p.m., Monday, December 16, 2024.**

Letters of Intent can be sent via mail to County of Aroostook, 144 Sweden St, Suite 1, Caribou, ME 04736 or via email to County Administrator, Ryan D. Pelletier at ryan@aroostook.me.us.

If you would like to be considered for Opioid Settlement funding you are required to submit a **Letter of Intent (LOI)** as part of the application submission. By submitting this form, you are notifying the County that you intend to apply for Opioid Settlement funds for an eligible project before the application deadline. If you choose not to apply after submitting the LOI, you do not need to notify the County.

Eligibility to submit an application does not imply final project approval or funding. It will be used to assess eligibility and identify a potential project. You will receive a Notification Eligibility Email from the County if your proposed project is determined to be eligible. If awarded, funds will not be available until after February 1, 2025. If the County Administration has any questions, they will contact you via email.

Limit of one LOI/Application per applying entity.

If approved, the project priority area chosen on the LOI, must be the same as the subsequently submitted Application for funding.

Opioid Settlement Funding Letter of Intent

1. Applicant Information

Agency/Organization:		Phone:	
Address:		Fax:	
City/Zip:		Email:	
Contact Person:		Title:	

Type of Agency/Organization (Select One):

<input type="checkbox"/> Public	<input type="checkbox"/> Private	<input type="checkbox"/> Government
<input type="checkbox"/> Non-Profit	<input type="checkbox"/> For-Profit	
Number of Years in Operation:		<input type="text"/>

2. Eligibility Categories (Select One)

<input type="checkbox"/> Prevention	<input type="checkbox"/> Recovery
<input type="checkbox"/> Treatment	<input type="checkbox"/> Harm Reduction

3. Priority Area (Select One)

<input type="checkbox"/> Youth Engagement
<input type="checkbox"/> Workforce Development
<input type="checkbox"/> Recovery Services Expansion
<input type="checkbox"/> Stigma Reduction
<input type="checkbox"/> Naloxone Training & Education

4. Population(s) Served (Select All)

<input type="checkbox"/> Children 0-3	<input type="checkbox"/> Young Adults 19-25
<input type="checkbox"/> Children 4-12	<input type="checkbox"/> Adults 25-62
<input type="checkbox"/> Teens 13-18	<input type="checkbox"/> Seniors 63+

5. Cost Estimates and Program Funding

Provide an estimated program cost, amount of Opioid Settlement funds to be requested and sources, amounts and dates secured for all anticipated cash matching funds. **A 25% cash match of the total funding award is recommended. Match amounts may come from any public or private source dependent upon Federal Funding requirements.**


Total Estimated Program Cost:	\$ <input type="text"/>	Opioid Settlement Fund Request:	\$ <input type="text"/>
-------------------------------	-------------------------	---------------------------------	-------------------------

Funding Source	Amount	Date Secured

% of Funds to be used for Direct Service(s)	<input type="text"/>
% of Funds to be used for Indirect Service(s)	<input type="text"/>

6. Program Information


Provide a clear, concise description of the proposed program using the space below. The scope of work should be very specific in identifying how the funds will be used to meet the Maine State-Subdivision Memorandum of Understanding and Agreement Regarding Use of Settlement Funds within eligible activity categories. For existing programs, describe the service, how it has been financed thus far, and why these funds are needed now. For new programs, describe the intent of the service, how the funds will be used, and how the program will be sustained. **Maximum of 1000 words.**



What barriers currently hinder program development and implementation and how will these barriers be overcome?



How will the effectiveness of the program be determined?



Applicant Certifications


- a. To the best of my knowledge and belief, the information in this Letter of Intent and all attached documentation is true and correct; and
- b. This Letter of Intent complies with all applicable State and Federal laws and regulations; and
- c. Approval of this Letter of Intent by the County to submit a final application does not imply final project approval or funding.

--	--	--

Signature of Authorized Person

Name of Organization

Date



*Aroostook County Commissioners Office
Aroostook County
144 Sweden Street, Suite 1
Caribou, Maine 04736*

**AROOSTOOK COUNTY
OPIOID SETTLEMENT FUND
APPLICATION**

Aroostook County is projected to receive a total settlement of approximately \$2.7 million dollars over the next 13.5 years from various Opioid Settlements. These are estimations only and actual payments may be more or less as settlements are finalized over the years to come. In this first round of funding, the County will make available a total of \$300,000 to be distributed equally across the 4 pillars (Treatment, Recovery, Prevention, and Harm Reduction). *It is very important to read the complete Maine State-Subdivision Memorandum of Understanding and Agreement Regarding Use of Settlement Funds to ensure all required information for the application is provided for maximum application scoring potential.*

Applicants must choose from eligible Opioid Settlement Fund Categories listed in the Memorandum of Understanding. All applications must be received via the mail or electronically by **4 p.m., Monday, January 20, 2025.**

Applications and other documents must be sent to County Commissioners' Office, 144 Sweden, St, Suite 1, Caribou, ME, 04736 or via email to ryan@aroostook.me.us.

Late submissions will not be accepted.

Note: This form must be completed as part of the application; additional information may be required upon assessment of the application. For further information: 207-493-3318.

Opioid Settlement Funding Application Overview

1. Introduction

Aroostook County Opioid Settlement Funds will provide funds to implement proposed programs/projects that deal with opioid related issues and meet the Maine State-Subdivision Memorandum of Understanding and Agreement Regarding Use of Settlement Funds.

Allowable Uses of Funds and Funding Restrictions: Specific to the J&J, Distributor, CVS, Teva, Allergan and Walmart settlements, funds must be spent on opioid remediation. Opioid Remediation is defined as: *Care, treatment, and other programs and expenditures (including reimbursement for past such programs or expenditures except where this Agreement restricts the use of funds solely to future Opioid Remediation) designed to address the misuse and abuse of opioid products, treat or mitigate opioid use or related disorders, or mitigate other alleged effects of, including on those injured as a result of, the opioid epidemic.*

Activities MUST meet the definition of opioid remediation, be an evidence-based strategy or promising practice and align with allowable uses outlined by [Exhibit E](#). These strategies include:

- **Core Strategies**
 - Naloxone or other FDA-approved drug to reverse opioid overdoses
 - Medication-assisted Treatment (MAT) distribution and other opioid-related treatment
 - Address the needs of pregnant and postpartum women
 - Expanding treatment for Neonatal Abstinence Syndrome (NAS)
 - Expansion of warm hand-off programs and recovery services
 - Treatment for incarcerated population
 - Prevention programs
 - Expanding syringe service programs
 - Evidence-based data collection and research analyzing the effectiveness of the abatement strategies within the state
- **Approved Uses - Prevention**
 - Prevent over-prescribing and ensure appropriate prescribing and dispensing of opioids
 - Prevent misuse of opioids
 - Prevent overdose deaths and other harms (harm reduction)
- **Approved Uses - Treatment**
 - Treat Opioid Use Disorder (OUD)
 - Support people in treatment and recovery
 - Connect people who need help to the help they need (connections to care)
 - Address the needs of criminal justice-involved persons
 - Address the needs of pregnant or parenting women and their families, including babies with NAS
- **Approved Uses – Other Strategies**
 - Supporting first responders
 - Leadership, planning and coordination
 - Training
 - Research

All approved funding awards are at the discretion of the Aroostook County Commissioners.

2. Letter of Intent as Opioid Settlement Funds Eligibility Requirement

Eligible applicants for Opioid Settlement funding are required to submit a Letter of Intent to Apply. Applicants submitting an Opioid Settlement Fund application without first submitting a Letter of Intent and receiving a Notification Eligibility Email from the County will have the application un-scored.

3. Matching Funds Recommendation

Applicants for Opioid Settlement funds are recommended to demonstrate they will provide a direct cash match of at least 25% of the total Opioid Settlement award. The match amount may come from any source public and/or private. This must be reflected on the Matching Funds Table contained on Page 5 of this Application Package. Firm letters of commitment for all cash matching funds must be attached to the table, if applicable.

4. Financial Commitments as a Scoring Requirement

Applications for projects not demonstrating a firm financial commitment as required in the application materials will be removed from the scoring process.

5. Maximum Opioid Settlement Fund Award Amounts:

- Treatment - \$75,000
- Recovery - \$75,000
- Prevention - \$75,000
- Harm Reduction - \$75,000

6. Application Limit

One application per applicant. Multiple applications will not be accepted. We recommend that all applicants submit applications for their priority category only.

7. Application Process

Step 1

A. Letter of Intent – see Number 2.

B. Completed Application

The application must provide a narrative description of the Strategy, Impact, and Sustainability relating to opioid remediation in the application. The applicant must complete the Application form and may only attach additional information if specifically requested. Please remember to answer briefly and as completely as possible within the allotted space. Each application will be rated on its own merit and in relation to all other applications.

C. Project Implementation

Following contract execution, the applicant will be awarded Opioid Settlement funds and will begin to implement their project.

8. Application Scoring

Members of the Opioid Task Force will assign a Point Total for each application reviewed. Review Point Totals will consist of the sum of the three scoring areas below and be determined by the total of each sub-scoring area.

- A. **Strategy – 35 points**
- B. **Impact – 40 points**
- C. **Sustainability – 25 points**

APPLICANT INFORMATION	
Name of Applicant/Organization/Entity:	
Non-Profit 501©(3) determination date: (provide letter, if applicable and available)	
Authorized Person/Title:	
Contact Name:	
Contact Address:	
Contact Title:	
Contact Email:	
Contact Phone Number:	

**Opioid Settlement Funds
Project Cost Breakdown**

Project Name	Opioid Settlement Funds Requested	Matching Funds	Total Project Cost

Matching Funds Table

Funding Source	Grant/Loan	Amount

Opioid Settlement Related Funds Already Awarded

Funding Source	Grant/Loan	Year	Amount

DETAILS OF THE OPIOID SETTLEMENT FUND REQUEST

Name of Project/Request:	
Eligible Opioid Settlement Funding Category:	
Dollar Amount of Settlement Funds Requested from County of Aroostook:	
Other Funds Invested in this Project and the Source of those funds:	
Period that the Funds will Cover and be Spent (from and to):	
Proposed Job Creation/Retention: (# jobs)	

Project Strategy

Project Strategy and Funding Eligibility Explanation

Explain your organization's opioid crisis remediation project and proposed description of how Opioid Settlement funding will impact your remediation efforts and outcomes within Aroostook County. Maximum 1000 words.

Project Strategy and Funding Eligibility Explanation-Continued

Project Impact

Target Demographic: _____

Number of People the project is expected to impact:_____

Project Impact Explanation

Explain in detail the purpose of the funds, how they will be expended, who will benefit, what demographic will be covered, what impact the funds are intended to have, the number of jobs created and/or retained, and how you will evaluate and measure success. Maximum 1000 words.

Project Impact Explanation-Continued

Sustainability

Will the project create or retain additional jobs after the initial project implementation and funding is expended? (Note: this is in addition to those jobs required to successfully implement the project). If YES, how many jobs will be projected to be created/retained in the future? _____

Sustainability Explanation

Explain in detail how the project will be sustained moving forward, future funding sources, and how additional jobs will be created/retained. Maximum 1000 words.

OFFICE USE ONLY